Combined Test – Screening 12

in the 12th-14th week of pregnancy
Objectives:
  • Probability calculation for trisomy 13, 18 and 21 and preeclampsia
    (alternative name for pregnancy poisoning)
  • Detection of any severe malformations

You are currently viewing a placeholder content from Vimeo. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.

More Information

In the combined test, the probability of Down syndrome (trisomy 21), trisomy 13 and 18 is calculated from several factors. These factors are the results of the first trimester ultrasound (neck folds, nasal bone and blood flow measurements), a maternal blood test and the age of the pregnant woman. In the blood test, we measure the serum concentration of fbhCG, PAPP-A and – like only a few institutes in Austria do – also the placental growth factor (Plgf).

During the first quarter ultrasound exam, an early examination of the fetal anatomy is also performed to rule out possible severe malformations.

As part of the combined test, we also clarify the likelihood of pre-eclampsia (alternative name for pregnancy poisoning). This can lead to premature birth and pregnancy complications. The main symptoms of pre-eclampsia are high blood pressure and protein excretion in the urine. To determine risk, the expectant mother’s blood pressure, placental blood flow, and biomarkers in the maternal blood are checked. If the risk is high, an almost side-effect free therapy can reduce the incidence of severe preeclampsia by more than 80 percent.

If the position of the baby allows it, we will be happy to take a 3D ultrasound image during the examination.

  • Since the blood test is performed directly in our prenatal center, we can inform you about the results of Screening 12 in a detailed discussion of the findings shortly after the examination.
  • Your ultrasound images are immediately available to you digitally.

We look forward to hearing from you!